Report overview
The global T-Cell Immunotherapy market size is estimated to be $xx million in 2023, and it will reach $xx million by 2032, growing at a CAGR of xx% during the forecast period from 2024 to 2032.
This report studies the T-Cell Immunotherapy market, covering market size for segment by type (CAR-T, TCR, etc.), by application (Stomach Cancer, Lung Cancer, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Adaptimmune Therapeutics, Autolus, Bluebird Bio, CARsgen Therapeutics, Celgene (Juno Therapeutics), etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).
This report provides detailed historical analysis of global market for T-Cell Immunotherapy from 2018-2023, and provides extensive market forecasts from 2024-2032 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the T-Cell Immunotherapy market.
Leading Players of T-Cell Immunotherapy including:
Adaptimmune Therapeutics
Autolus
Bluebird Bio
CARsgen Therapeutics
Celgene (Juno Therapeutics)
Cellectis
Innovative Cellular Therapeutics
Novartis
Sinobioway Cell Therapy
Altor Bioscience Corporation
Gilead (Kite Pharma)
Takara Bio
Unum Therapeutics
Pfizer
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Collectis
Allogene Therapeutics
Celyad
Market split by Type:
CAR-T
TCR
TIL
Market split by Application:
Stomach Cancer
Lung Cancer
Colorectal Cancer
Esophagus Cancer
Pancreatic Cancer
Market split by Sales Channel:
Direct Channel
Distribution Channel
Market split by Region/Country:
North America (United States and Canada)
Europe (Germany, UK, France, Italy, Spain, and Russia, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia, etc.)
South America (Brazil, Mexico, and Argentina, etc.)
Middle East & Africa (Turkey, UAE, Saudi Arabia, and South Africa, etc.)
If you have any special requirements, please let us know and we can provide you the customized report as you want.
